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Abstract
Optical coherence tomography based computational flow dynamic (CFD) modeling provides detailed information about the 
local flow behavior in stented/scaffolded vessel segments. Our aim is to investigate the in-vivo effect of strut thickness and 
strut protrusion on endothelial wall shear stress (ESS) distribution in ArterioSorb Absorbable Drug-Eluting Scaffold (Arte-
rioSorb) and Absorb everolimus-eluting Bioresorbable Vascular Scaffold (Absorb) devices that struts with similar morphol-
ogy (quadratic structure) but different thickness. In three animals, six coronary arteries were treated with ArterioSorb. At 
different six animals, six coronary arteries were treated with Absorb. Following three-dimensional(3D) reconstruction of the 
coronary arteries, Newtonian steady flow simulation was performed and the ESS were estimated. Mixed effects models were 
used to compare ESS distribution in the two devices. There were 4591 struts in the analyzed 477 cross-sections in Absorb 
(strut thickness = 157 µm) and 3105 struts in 429 cross-sections in ArterioSorb (strut thickness = 95 µm) for the protrusion 
analysis. In cross-section level analysis, there was significant difference between the scaffolds in the protrusion distances. 
The protrusion was higher in Absorb (97% of the strut thickness) than in ArterioSorb (88% of the strut thickness). ESS was 
significantly higher in ArterioSorb (1.52 ± 0.34 Pa) than in Absorb (0.73 ± 2.19 Pa) (p = 0.001). Low- and very-low ESS 
data were seen more often in Absorb than in ArterioSorb. ArterioSorb is associated with a more favorable ESS distribution 
compared to the Absorb. These differences should be attributed to different strut thickness/strut protrusion that has signifi-
cant effect on shear stress distribution.
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Introduction
As a promising technology, bioresorbable scaffolds (BRS) 
introduced new terms such as degradation, disappearance 
and recovery in vasomotricity, into the interventionalists’ 
jargon. However, relatively high thrombosis events have 
been a serious setback in the development of this technol-
ogy and jeopardized the change in the paradigm in per-
cutaneous coronary revascularization [1, 2]. In the era of 
metallic DES, beside the implantation techniques, the stent 
design and strut thickness were deemed responsible for the 
adverse events [3, 4].
Stent/scaffold implantation creates a new endoluminal 
surface with near-wall blood flow interference that have 
major mechano-transduction impact [5]. Compared to pre-
implantation, in instrumented vessel segments disturb the 
blood flow in relation to the scaffold design, particularly 
strut geometry and strut thickness [6, 7]. The blood rheol-
ogy, local hemodynamic factors, prominently shear stress, 
play an important role in the vessel wall biology [5]. While 
laminar and relatively high shear stress is athero-protec-
tive and holds the platelets and endothelium quiescent, 
low and oscillatory shear stress upregulates inflamma-
tory oxidative reactions, can induce thrombus formation, 
promote reactive neointima and subject the vessel wall to 
atherosclerotic changes [8, 9].
Optical coherence tomography (OCT) based computa-
tional fluid dynamics (CFD) model provides detail infor-
mation on the local flow environment in stented/scaffolded 
vessel segments [10]. Our aim was to investigate in-vivo 
the effect of quadratic strut designs and strut protrusion 
on shear stress distribution in the vessel segments treated 
with BRS.
Methods
Study design and animal models
We analyzed data from Yucatan mini pigs implanted with 
Arteriosorb™ Absorbable Drug-Eluting Scaffold (Arteri-
oSorb, Arterius Ltd., Leeds, UK) and Absorb everolimus-
eluting Bioresorbable Vascular Scaffold (Absorb BVS, 
Abbott Vascular, Santa Clara, CA, USA). In three animals, 
six coronary arteries were treated with ArterioSorb and in 
other six animals, six coronary arteries were treated with 
Absorb. Study protocol was approved by the Institutional 
Animal Care and Use Committee of the testing facility 
(AccelLAB Inc., Boisbriand, Quebec, Canada) and were 
in compliance with the Canadian Council on Animal Care 
regulations. Animal husbandry, medication administration, 
and stent implantation were performed according to stand-
ards. The Testing Facility is accredited by the Association 
for Assessment and Accreditation of Laboratory Animal 
Care (AAALAC) and the Canadian Council on Animal 
Care (CCAC) [11].
Scaffold design
ArterioSorb is made up of poly l-lactic acid(PLLA), 
coated with a layer of poly d,l-lactic acid (PDLLA) elut-
ing rapamycin (1.45 µg/mm2). ArterioSorb is manufac-
tured using melt processing (extrusion) and die-drawing 
(solid-phase orientation) techniques with strut thicknesses 
of 95 µm and 120 µm. The strut width is 170 µm. Arte-
rioSorb is composed of an 8-cell open-cell design with 
smaller cells at the center to improve the radial strength 
and cell connectors distributed in a spiral design (Fig. 1). 
The vessel coverage ratio in ArterioSorb is 29%. Arteri-
oSorb has two pairs of radiopaque markers at distal and 
proximal edge of the scaffold.
Absorb is produced from PLLA, coated with a layer of a 
1:1 mixture of an amorphous matrix of PDLLA and elutes 
everolimus (8.2 µg/mm2). Absorb is manufactured using 
extrusion and laser machining techniques, has 157 µm 
strut thickness and design of in-phase zig-zag hoops linked 
with bridges (Fig. 1). The strut width is 176 µm. The ves-
sel coverage ratio of Absorb is 27%. Absorb has two pairs 
of radiopaque markers at distal and proximal edge of the 
scaffold.
Fig. 1  The design of the Absorb bioresorbable vascular scaffold 
(absorb) (a) and ArterioSorb bioresorbable scaffold (ArterioSorb) 
(b). In Absorb, the length of the cells are the same where as in Arteri-
oSorb, the cells in the middle of the device are smaller than the cells 
in the proximal and distal of the scaffold
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Scaffold implantation
To prevent any effect of swirling-flow due to vessel curva-
ture, on the scaffolded segment ESS distribution, we didn’t 
include the cases with increased curvature. After pre-implant 
angiography was obtained, the target scaffold diameter was 
calculated from the reference vessel diameter which was 1.1 
× (with a range of 1.05 × to 1.15 ×) the reference vessel 
diameter. Then the device was introduced into the selected 
artery by advancing the balloon catheter through the guide 
catheter and over the guidewire to the deployment site. The 
scaffolds were deployed according to the Interventionalist’s 
judgment using the product compliance charts and target 
vessel size as a guide, to achieve a targeted balloon-to-
artery ratio of 1.1:1 with a range of 1.05:1 to 1.15:1. The 
balloon was not deployed below nominal pressure or higher 
than Rated Burst Pressure. The balloon was inflated slowly, 
at a 1 atm increment every 2 seconds until the scaffold is 
expanded. The final pressure should be maintained for at 
least 30 s. An angiogram of the balloon at full inflation was 
recorded and the maximal inflation pressure was noted. Post-
dilatation was performed in all cases using a non-compliant 
balloon or by a semi-compliant balloon to ensure good appo-
sition of the scaffold, and the target balloon to artery ratio 
met the requirements, for vessel diameters up to 3.20 mm at 
the discretion of the operator.
Data acquisition
X-ray angiography was performed using Siemens Axiom 
cardiac angiography system (Siemens, Erlangen, Germany). 
For the post-implantation and post-dilatation angiographies, 
two projections with at least 25 degrees apart from each 
other were selected. When multiple balloon inflations were 
performed, the image with the highest pressure was used for 
analysis. Quantitative coronary angiography (QCA) meas-
urements were obtained from these images using the QAn-
gio® XA 7.3 system and Medis QCA-CMS 6.0 software 
(Medis, Leiden, The Netherlands).
OCT was performed before and after scaffold implan-
tation in all treated coronary arteries, using a frequency-
domain (FD) OCT system (Ilumien OCT Intravascular 
Imaging System; St. Jude Medical, St. Paul, MN, USA). 
When post-dilatation was performed, OCT was performed 
following each post-dilatation and at the end of the pro-
cedure to document OCT parameters at each successive 
stage. A non-occlusive flushing technique was used for 
blood clearance by injection of contrast media. After 
administration of nitrates (0.2 mg NTG intracoronary), the 
FD-OCT imaging catheter was advanced into the coronary 
artery in rapid exchange technique. The OCT catheter was 
advanced beyond the device, into the distal vessel, and 
pulled back to a point proximal to the device frequently to 
the ostium of the treated vessel. After FD-OCT catheter 
placement, blood was cleared by injection of iso-osmolar 
contrast. The FD-OCT pull-back was started as soon as 
the artery was cleared from blood and stopped when the 
imaging core reached the guiding catheter. Qualitative 
analysis of the captured images was then be performed 
(such as strut malapposition) off line. The acquired data 
were stored in DICOM format and transferred to a work-
station for further analysis. The OCT analysis was per-
formed using QCU-CMS software (version 4.69, Leiden 
University Medical Center, Leiden, The Netherlands) [12].
Protrusion analysis by optical coherence 
tomography
For protrusion analysis, the protrusion distances were esti-
mated semi-automatically using a special version of QCU-
CMS software (version 4.69, Leiden University Medical 
Center, Leiden, The Netherlands) [12]. The protrusion 
analysis in OCT was performed in the scaffolded segment 
at every 200 µm longitudinal interval using a methodology 
presented previously [12]. Interobserver reproducibility 
analysis in protrusion in quadratic struts has been published 
previously [12].
Coronary artery reconstruction
Coronary artery reconstruction was conducted implementing 
a validated methodology [13]. In X-ray angiographic and 
OCT images, anatomical landmarks (i.e. side branches) and 
the radiopaque markers were identified and used to define 
the scaffolded segment and proximal–distal native vessel 
segments. After matching, the OCT images portraying the 
scaffolded and the proximal–distal non-scaffolded native 
vessel segments were analyzed at a 100 micron (µm) interval 
in the scaffolded segment and 400 µm interval in the native 
vessel segments. The flow area was traced and defined in the 
native segments by the luminal border and in the scaffolded 
segments by the adluminal side of the struts and by the ves-
sel luminal surface borders between the struts [14].
Two post-procedure end-diastolic angiographic images 
with at least 25º-angle difference showing the analyzed OCT 
frames (region of interest, ROI) with minimal foreshorten-
ing were selected. In these images, the luminal borders were 
delineated for the ROI and processed to extract the luminal 
centerline which was then used for the three-dimensional 
(3D) luminal centerline of the ROI [13]. The borders of flow 
area identified on OCT images were then mounted perpen-
dicularly onto the luminal centerline and side-branches seen 
in both OCT and angiographic images were utilized to estab-
lish the absolute orientation of the OCT frames [13].
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Computational flow dynamics study
The reconstructed models were processed with CFD tech-
niques. A finite volume mesh was generated and then blood 
flow simulation was performed. ESS was estimated by solv-
ing the 3D Navier–Stokes equations (ANSYS Fluent, Can-
onsburg, Pennsylvania) [15]. To assess the effect of scaf-
fold designs on the local flow patterns, the mesh density 
around the struts and within the boundary layer of the flow 
between the struts was increased to have an average element 
edge equal to 1/5 of the strut thickness. Blood was assumed 
to be a homogeneous, Newtonian fluid with a viscosity of 
0.0035 Pa.s and a density of 1050 kg/m3. A steady flow 
profile was simulated at the inflow of the 3D models. Blood 
flow for each reconstruction was estimated by measuring, 
in the 2 angiographic projections, the number of frames 
required for the contrast agent to pass from the inlet to the 
outlet of the reconstructed segment, the volume of the recon-
structed segment and the cine frame rate [15]. The arterial 
wall was considered to be rigid and no-slip conditions were 
implemented at the scaffold surface. At the outlet of the 
model zero pressure conditions were imposed. ESS at ves-
sel luminal surface was calculated as the product of blood 
viscosity and the gradient of blood velocity at the wall [16]. 
The ESS was measured in the native and the scaffolded seg-
ment around the circumference of the lumen per 5° interval 
(sector) and along the axial direction per 200 µm interval 
with the use of an in-house algorithm [16].
Statistical analysis
Continuous variables were tested for normality distribu-
tion with Kolmogorov–Smirnov test and are presented 
as mean ± SD or median (interquartile range) as appro-
priate. Categorical variables are presented as counts and 
percentages. Continuous variables were compared by the 
Kruskal–Wallis test or Mann Whitney-U test. Categori-
cal variables were compared by the Pearson Chi square 
test. Since the data have multi-level structure and unbal-
anced design, mixed effects model was used for statistical 
analysis. To compare the ESS values in different scaffold 
groups, the multi-level model was initially built with fixed 
effects on scaffold type, cross-sectional area and interac-
tion of the scaffold type with cross-sectional area and ran-
dom effects on animal ID, scaffold ID and cross-section 
ID. After comparing different models using maximum 
likelihood, best fitted model was selected. A p < 0.05 was 
considered statistically significant. Analyses were done 
using the statistical analysis program SPSS V.21, R V. 
3.2.3 and the R package lme4 [17].
Results
Three left anterior descending coronary artery (LAD) and 
3 right coronary arteries (RCA) were implanted with an 
ArterioSorb and 1 LAD, 3 left circumflex (LCx) and 2 
RCA with an Absorb. Scaffold dimensions, the flow veloc-
ities for each investigated vessel and procedural param-
eters are shown in Tables 1 and 2. In QCA, the dimensions 
of scaffolded segment and non-scaffolded segments are 
shown in Table 3. Mean lumen diameters and areas are 
comparable between the two scaffold groups.
In OCT, in the device level analysis in-scaffold mean 
lumen area were comparable in the two scaffold groups. 
In the cross-section level analysis, in-scaffold mean lumen 
area was slightly higher in Absorb (7.62 ± 1.10  mm2) com-
pared with the ArterioSorb (7.35 ± 0.86  mm2) (p = 0.052) 
(Table 4).
Table 1  Scaffold dimensions 
and flow velocities for 
ArterioSorb and Absorb
Scaffold Animal Vessel Scaffolded 
vessel seg-
ment
Scaffold size
(mm)
Mean lumen diameter 
after post-dilatation
(mm)
Flow 
velocities 
(m/s)
ArterioSorb-1 A LAD Distal 3.0 × 14 3.28 0.181
ArterioSorb-1 A RCA Mid 3.0 × 14 3.37 0.098
ArterioSorb-1 B LAD Mid 3.0 × 14 3.32 0.138
ArterioSorb-1 B RCA Proximal 3.0 × 14 3.00 0.135
ArterioSorb-1 C LAD Mid 3.0 × 14 3.16 0.155
ArterioSorb-1 C RCA Distal 3.0 × 14 3.20 0.147
Absorb BVS-1 E RCA Mid 3.0 × 18 3.32 0.104
Absorb BVS-2 D LCx Mid 3.0 × 18 3.06 0.103
Absorb BVS-3 F LCx Proximal 3.0 × 18 3.32 0.091
Absorb BVS-4 G LAD Mid 3.0 × 18 3.16 0.172
Absorb BVS-5 I RCA Mid 3.0 × 15 3.16 0.108
Absorb BVS-6 H LCx Mid 3.0 × 18 3.32 0.104
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Table 2  Procedural details Scaffold Absorb (n = 6) ArterioSorb (n = 6) p
Implanted vessel
 LAD/LCx/RCA (n) 1/3/2 4/2/5
Device
 Device nominal size (mm) 3.0 ± 0 3.0 ± 0 0.12
 Device length (mm) 17.5 ± 1.22 14.00 ± 0 < 0.001
 Maximum deployment pressure (atm) 7.0 ± 0 14.71 ± 2.94
Pre-dilatation
 Pre-dilatation performed, n (%) 0 (0%) 0 (0%) 1.00
Post-dilatation
 Post dilatation performed, n (%) 6 (100%) 6 (100%) 1.00
 Post dilatation balloon type
  Semi-compliant balloon, n (%) 0 (0%) 0 (0%)
  Non-compliant balloon, n (%) 6 (100%) 6 (100%) 1.00
 Maximum post-dilatation balloon pressure (atm) 8.5 ± 2.7 16.2 ± 3.0 0.001
 Maximum expected post-dilatation balloon size (mm) 3.37 ± 0.093 3.65 ± 0.59 0.08
Table 3  QCA variables in scaffold groups
Absorb (157 µm)
n = 6
ArterioSorb (95 µm)
n = 6
p
Mean lumen diameter pre-implantation (scaffolded segment) (mm) 2.84 ± 0.15 2.83 ± 0.16 0.11
Mean lumen area pre-implantation (scaffolded segment)  (mm2) 6.74 ± 0.45 6.58 ± 0.77 0.67
Mean lumen diameter post-implantation (scaffolded segment) (mm) 3.22 ± 0.11 3.03 ± 0.25 0.07
Mean lumen area post-implantation (scaffolded segment)  (mm2) 7.49 ± 0.63 7.21 ± 1.58 0.69
Mean lumen diameter post-implantation (non-scaffolded segment) (mm) 3.19 ± 0.12 2.95 ± 0.19 0.045
Mean lumen area post-implantation (non-scaffolded segment)  (mm2) 7.36 ± 0.85 6.83 ± 1.25 0.038
Table 4  OCT analyses results in scaffold groups
Data are expressed as n (%) and mean ± standard deviation
Absorb ArterioSorb p
(n = 6) (n = 6)
Device level
 In-scaffold mean lumen area  (mm2) 7.77 ± 0.70 7.33 ± 0.69 0.074
 Distal reference mean lumen area  (mm2) 5.08 ± 1.31 6.19 ± 1.45 0.194
 Proximal reference mean lumen area  (mm2) 7.46 ± 2.63 7.81 ± 0.49 0.751
 Mean scaffold area  (mm2) 8.10 ± 0.61 7.76 ± 0.70 0.190
(n = 478) (n = 429)
Cross-section level
 In-scaffold mean lumen area  (mm2) 7.62 ± 1.10 7.35 ± 0.86 0.052
 Distal reference mean lumen area  (mm2) 5.07 ± 1.42 6.20 ± 1.41 0.465
 Proximal reference mean lumen area  (mm2) 6.85 ± 2.20 7.74 ± 0.93 0.843
 Mean scaffold area  (mm2) 8.00 ± 0.59 7.77 ± 0.87 < 0.0001
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Protrusion analysis
There were 4591 struts in 477 cross-sections from Absorb 
and 3105 struts in 429 cross-sections from ArterioSorb in 
the protrusion analysis. There were 128 and 25 malapposed 
struts in Absorb and ArterioSorb, respectively. The protru-
sion analyses were performed in device and cross-section 
levels (Table 5). In device level analysis, ArterioSorb struts 
protruded (84 ± 6 µm) in the vessel wall less than in Absorb 
(153 ± 18 µm) (p = 0.004). In cross-section level analysis, 
there was significant difference between the two scaffolds 
in strut protrusion (153 ± 137 µm for Absorb, 84 ± 12 µm 
for ArterioSorb; p < 0.0001), that can be attributed to dif-
ference in strut thicknesses. The protrusion was higher in 
Absorb (97% of the strut thickness) than in ArterioSorb 
(88% of the strut thickness). When the protrusion distance 
was adjusted according to the lumen diameters, the ratio 
of protrusion distance/mean lumen diameter was higher in 
Absorb BVS (0.052 ± 0.0038) compared with the Arteri-
oSorb (0.028 ± 0.0045) (< 0.0001).
Endothelial shear stress analysis
There were several layers of grouping within study data; nine 
animals (level 3) received scaffold implants in their coronary 
arteries, and similar types of the scaffolds were used in dif-
ferent vessels within the same animal. Each scaffolded seg-
ment had several cross-sections (level 2) and in each cross-
section the ESS was quantified circumferentially in 5-degree 
sectorial subunits (level 1). ESS was significantly higher in 
ArterioSorb (1.52 ± 0.34 Pa) than in Absorb (0.73 ± 2.19 Pa) 
(p = 0.001) (Table 5). In both types of scaffolds, there were 
inverse correlations between strut protrusion and ESS. Low- 
(< 1.0 Pa) and very-low (< 0.5 Pa) ESS estimations were 
seen more often in Absorb implanted vessel segments as 
compare to the ArterioSorb (Fig. 2).
Discussion
In this study, we investigated two different types of BRS 
with similar strut geometry but different strut thicknesses in 
porcine coronary artery models. The findings can be summa-
rized as follows; (1) Strut protrusion was higher in Absorb 
(97% of the strut thickness) than in ArterioSorb (88% of the 
Table 5  Protrusion and ESS results
Absorb ArterioSorb p
(n = 6) (n = 6)
Device level
 Protrusion distance (µm) 153 ± 18 84 ± 6 0.004
 Protrusion distance/mean lumen diameter 0.019 ± 0.002 0.012 ± 0.002 < 0.0001
 In-scaffold mean ESS (Pa) 0.73 ± 0.25 1.51 ± 0.22 0.03
 Proximal non-scaffolded segment mean ESS (Pa) 1.40 ± 0.06 1.08 ± 0.30 0.04
 Distal non-scaffolded segment mean ESS (Pa) 1.31 ± 0.07 1.39 ± 0.25 0.26
(n = 478) (n = 429)
Cross-section level
 Protrusion distance (µm) 153 ± 137 84 ± 12 < 0.0001
 Protrusion distance/mean lumen diameter 0.052 ± 0.0038 0.028 ± 0.0045 < 0.0001
 In-scaffold mean ESS (Pa) 0.73 ± 2.19 1.52 ± 0.34 0.001
 Proximal non-scaffolded segment mean ESS (Pa) n = 124
1.41 ± 0.36
n = 170
1.00 ± 0.47
0.355
 Distal non-scaffolded segment mean ESS (Pa) n = 147
1.29 ± 0.46
n = 260
1.39 ± 0.69
0.647
Fig. 2  The low- and very-low ESS (median ESS per-cross-section) 
were recorded much more in Absorb than ArterioSorb
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strut thickness). (2) The decreased protrusion resulted noted 
in ArterioSorb in higher ESS in these scaffolds compared to 
the Absorb. (3) Due to less strut protrusion in ArterioSorb, 
low and very low ESS were seen less in ArterioSorb than 
Absorb.
Stent/scaffold induced hemodynamic changes are one of 
the decisive determinants of PCI outcomes [13, 15, 18–20]. 
Several factors, such as vessel curvature in the treated seg-
ment, residual stenosis following device implantation, local 
deformation at the edges of the implanted device, tissue 
protrusion between the struts, scaffold design properties 
are factors responsible for the hemodynamic repercussion 
following stent/scaffold implantation. Among these factors, 
stent/scaffold design and strut apposition status are of utmost 
importance due to a relationship between new established 
luminal surface and local flow behaviors. Shear stress has 
been demonstrated to be inversely related with neointimal 
healing process following stent/scaffold implantation [21]. 
In this relationship, strut thickness and protrusion emerge 
as cornerstone factors for the flow behaviors post-PCI [22]. 
Besides the micro level changes around the struts, fluid shear 
stress at a macro level is influenced by the vessel luminal 
dimensions after stent/scaffold implantation.
In the present report, two types of scaffolds were 
implanted in straight vessels. Both scaffolds have square-
shaped strut designs, however ArterioSorb has thinner strut 
thickness of 95 µm which obviously induces less flow sepa-
rations compared to thicker struts of Absorb (Fig. 3) [6, 23]. 
Less flow separation will subject the newly set vessel surface 
to relatively higher endothelial wall shear stress (Fig. 4). In 
ArterioSorb, the final luminal area post-implantation was 
slightly smaller than the Absorb and there was an obvious 
difference in the strut protrusion between the scaffolds. After 
adjusting the protrusion distances according to the final 
luminal dimensions, ArterioSorb had lower ratio of protru-
sion distance/luminal diameter as compared to the Absorb.
The inter-strut distance has impact on the recovery of the 
laminar flow between the struts [24]. The inter-strut distance 
should be at least six times the strut thickness [24]. Arteri-
oSorb has maximum inter-strut distance of 1.4 mm which is 
longer than in Absorb (1.0 mm) and provides a significant 
advantage for the recovery of laminar flow resulting in more 
physiological ESS between the struts (Fig. 5).
Bare metal stent (BMS) studies have emphasized that 
stent design influences clinical outcomes [3, 25]. Anti-pro-
liferative drugs has changed the paradigm in drug-eluting 
Fig. 3  The protrusion in Arte-
rioSorb was less than Absorb, 
due to the thinner struts of 
ArterioSorb
Fig. 4  Due to thinner struts in 
ArterioSorb (a), the shear stress 
magnitudes were relatively 
higher than in Absorb (b). In the 
cross-sections from Absorb and 
ArterioSorb, mean ESS were 
0.6 Pa and 1.9 Pa, respectively
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metallic stents as the drug reduced the vessel wall prolifera-
tive reaction and prolonged vessel wall healing process. In 
BRS, the findings of the recently reported clinical studies 
raised concerns about the potential risk of scaffold thrombo-
sis that have been at least partially attributed to BRS design 
[26]. The non-streamlined strut design has significant effects 
on local flow patterns even in highest coronary flow that can-
not be omitted [26, 27]. To address this limitation, industry 
has focused on more “hemocompatible” scaffold designs 
with different strut thicknesses, alignment and geometry. 
The present study has shown that in vivo OCT based CFD 
modeling can be used to investigate the hemodynamic per-
formance of different scaffolds. CFD may have a significant 
role in the optimization of the scaffold design in favor of 
coronary flow [28]. In addition to high-tech CFD studies, 
protrusion analysis on OCT appears to contribute to opti-
mized implantation which is critical for satisfactory results 
at follow-up after PCI [29, 30].
Limitations
A major limitation of the present study is the fact that 
scaffold implantation was performed in healthy coronary 
arteries. Therefore, it was not possible to investigate the 
implications of scaffold under-expansion or the effect of the 
underlying treated plaque on strut protrusion which is likely 
to determine the local hemodynamic features.
Secondly, one of the main limitation was the small sample 
size. Several criteria were implemented for filtering suitable 
cases. To prevent any effect of swirling-flow due to vessel 
curvature, on the scaffolded segment ESS distribution, we 
didn’t include the cases with curvature. Also, the cases with-
out two angiographic projections at least with > 25-degree 
difference couldn’t be reconstructed. However, total strut and 
cross-section numbers provided well-fitted statistical models 
for getting reliable conclusions.
Thirdly, the treated vessels (LAD, LCx and RCA) were 
different and there was an uneven distribution for the vessels 
treated between the study groups. Moreover, vessel diame-
ters, the deployment pressures and the balloon pressures dur-
ing post-dilation were different which might induce potential 
differences in the flow between the treated segments.
It’s well known that side-branches can impact on the 
flow and shear stress distribution in the scaffolded segment 
[7]. One of the limitations of this study was that we did not 
include in the reconstructions of the side branches. How-
ever, there was no side branches bigger than 1.5 mm in the 
scaffolded segments in our data which could dissipate the 
concerns about that point.
Conclusion
In vivo OCT based CFD modeling can be used to evalu-
ate the implications of scaffold configuration on the local 
hemodynamic forces. The thinner strut of ArterioSorb has 
less effect on the ESS patterns compared to the thicker struts 
of the Absorb. Further research is required to examine the 
potential value of the in vivo CFD modeling in optimizing 
scaffold configuration and clinical outcomes.
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Fig. 5  The inter-strut distance is 1.0  mm in Absorb (a) whereas 
1.4  mm in ArterioSorb (b). The wider inter-strut distance provides 
more space to ArterioSorb to regain laminar flow and more physi-
ological ESS over the wall boundary
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